Biotech Values

[gfp927z]

Dew, Concerning Maxygen, I was wondering if your interest in them is primarily for their Hep C program, or perhaps more for the entire pipeline? Their programs do look interesting but all look to be very early stage. I thought their G34 neutropenia program looked particularly interesting. I also wonder if in doing the various spinoffs over the years they have perhaps given away too much? The spinoffs did eliminate the need to raise money and dilute the stock, which was admirable. Thanks for any insights.